Literature DB >> 33239412

Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease.

Peter Rossing1.   

Abstract

Entities:  

Keywords:  aldosterone; chronic kidney disease; diabetes; microalbuminuria; mineralocorticoid receptor antagonists

Year:  2020        PMID： 33239412      PMCID： PMC7769027          DOI： 10.2215/CJN.16201020

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.

Authors:  Jonatan Barrera-Chimal; Sophie Girerd; Frederic Jaisser
Journal:  Kidney Int       Date:  2019-03-13       Impact factor: 10.612

Review 2.  Nonsteroidal antagonists of the mineralocorticoid receptor.

Authors:  Peter Kolkhof; Christina Nowack; Frank Eitner
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-09       Impact factor: 2.894

3.  Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.

Authors:  Hiddo J L Heerspink; Tom Greene; Hocine Tighiouart; Ron T Gansevoort; Josef Coresh; Andrew L Simon; Tak Mao Chan; Fan Fan Hou; Julia B Lewis; Francesco Locatelli; Manuel Praga; Francesco Paolo Schena; Andrew S Levey; Lesley A Inker
Journal:  Lancet Diabetes Endocrinol       Date:  2019-01-08       Impact factor: 32.069

4.  Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.

Authors:  Nete Tofte; Morten Lindhardt; Katarina Adamova; Stephan J L Bakker; Joachim Beige; Joline W J Beulens; Andreas L Birkenfeld; Gemma Currie; Christian Delles; Ingo Dimos; Lidmila Francová; Marie Frimodt-Møller; Peter Girman; Rüdiger Göke; Tereza Havrdova; Hiddo J L Heerspink; Adriaan Kooy; Gozewijn D Laverman; Harald Mischak; Gerjan Navis; Giel Nijpels; Marina Noutsou; Alberto Ortiz; Aneliya Parvanova; Frederik Persson; John R Petrie; Piero L Ruggenenti; Femke Rutters; Ivan Rychlík; Justyna Siwy; Goce Spasovski; Marijn Speeckaert; Matias Trillini; Petra Zürbig; Heiko von der Leyen; Peter Rossing
Journal:  Lancet Diabetes Endocrinol       Date:  2020-03-02       Impact factor: 32.069

5.  Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Authors:  Sadayoshi Ito; Kenichi Shikata; Masaomi Nangaku; Yasuyuki Okuda; Tomoko Sawanobori
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-27       Impact factor: 8.237

Review 6.  Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.

Authors:  Jing Hou; Weiquan Xiong; Ling Cao; Xiangqiong Wen; Ailing Li
Journal:  Clin Ther       Date:  2015-08-05       Impact factor: 3.393

7.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Authors:  George L Bakris; Rajiv Agarwal; Juliana C Chan; Mark E Cooper; Ron T Gansevoort; Hermann Haller; Giuseppe Remuzzi; Peter Rossing; Roland E Schmieder; Christina Nowack; Peter Kolkhof; Amer Joseph; Alexander Pieper; Nina Kimmeskamp-Kirschbaum; Luis M Ruilope
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

8.  Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment.

Authors:  Ian H de Boer; M Luiza Caramori; Juliana C N Chan; Hiddo J L Heerspink; Clint Hurst; Kamlesh Khunti; Adrian Liew; Erin D Michos; Sankar D Navaneethan; Wasiu A Olowu; Tami Sadusky; Nikhil Tandon; Katherine R Tuttle; Christoph Wanner; Katy G Wilkens; Sophia Zoungas; Lyubov Lytvyn; Jonathan C Craig; David J Tunnicliffe; Martin Howell; Marcello Tonelli; Michael Cheung; Amy Earley; Peter Rossing
Journal:  Kidney Int       Date:  2020-07-10       Impact factor: 10.612

9.  Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.

Authors:  Sadayoshi Ito; Naoki Kashihara; Kenichi Shikata; Masaomi Nangaku; Takashi Wada; Yasuyuki Okuda; Tomoko Sawanobori
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-25       Impact factor: 8.237

10.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.